Рыночные новости
Заголовки по акциям и крипте из Alpaca. Храним 7 дней. Всего: 9776.
-
UBS Adjusts Price Target for SSR MiningUBS has lowered its price target for SSR Mining from $39 to $37.
-
Analysts Raise 12-Month Price Target for Alamar Biosciences, Inc.Following recent updates, the average 12-month price target for Alamar Biosciences, Inc. has been increased to $36.60, reflecting a 21% potential upside.
-
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and Thyroid Eye DiseaseSepterna, Inc. has selected SEP-204 as its first-in-class development candidate for treating Graves' disease and thyroid eye disease (TED) and released initial preclinical data.
-
Morgan Stanley Lowers Price Target on Upstart Holdings to $24.00Morgan Stanley has revised its price target for Upstart Holdings, Inc., reducing it from $35.00 to $24.00.
-
JPMorgan Downgrades Group 1 Automotive to UnderweightJPMorgan has downgraded Group 1 Automotive from Neutral to Underweight, setting a price target of $250.
-
Sprott Inc. Announces Third Quarter 2026 Financial ResultsSprott Inc. reported its financial results for the third quarter of 2026, highlighting revenue of $75.1 million and earnings per share of $0.86.
-
Peabody Board Declares Quarterly DividendPeabody Energy Corporation declared a quarterly cash dividend of $0.075 per share, payable in December 2026.
-
National Energy Services Reunited Corp. Secures $747.1 Million Refinancing AgreementNational Energy Services Reunited Corp. (NESR) has entered into a new secured facilities agreement to refinance existing debt and support ongoing operations.
-
Peabody Reports Third Quarter 2026 Financial ResultsPeabody Energy Corporation reported a net loss of $32.8 million for the third quarter of 2026, while announcing a $40 million reduction in capital expenditure guidance and lowered volume expectations for the year.
-
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 at ASH 2026Immunome, Inc. announced it will present initial first-in-human clinical data from its ongoing Phase 1 study of IM-1021, an ROR1-targeted antibody-drug conjugate, at the 68th American Society of Hematology Annual Meeting.
-
Beam Therapeutics to Present Updated BEACON Trial Data at 68th ASH Annual MeetingBeam Therapeutics announced it will present updated clinical data from its BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel) for sickle cell disease at the upcoming American Society of Hematology (ASH) Annual Meeting.
-
NETSCOUT Announces Participation in Upcoming Investor ConferencesNETSCOUT Systems, Inc. announced that key executives, including CFO Tony Piazza, will participate in the RBC Capital Markets Global Technology, Internet, Media and Telecommunications (TIMT) Conference.
-
Penguin Solutions Announces Agreement to Sell Cree LED Business to Transom Capital GroupPenguin Solutions has entered into a definitive agreement to divest its Cree LED business to private equity firm Transom Capital Group.
-
Stifel Lowers Amdocs Price Target to $46Stifel has maintained its Buy rating on Amdocs Limited while lowering the price target from $71 to $46.
-
Analysts Adjust Price Targets for Revvity Following Q3 EarningsMultiple financial institutions, including Stifel Nicolaus, Goldman Sachs, and JPMorgan, updated their price targets for Revvity on November 4, 2026, following the company's third-quarter earnings report.
-
Keefe Bruyette & Woods Downgrades Cipher Digital to Market PerformKeefe Bruyette & Woods downgraded Cipher Digital to Market Perform with a price target of $9.50.
-
MoffettNathanson Raises Price Target on Cinemark Holdings to $46MoffettNathanson has increased its price target for Cinemark Holdings, Inc. from $41 to $46 while maintaining a Buy rating.
-
Wedbush Raises Price Target on Cinemark Holdings to $46Wedbush has increased its price target for Cinemark Holdings, Inc. from $45 to $46 while maintaining an Outperform rating.
-
Morgan Stanley Raises Price Target on Broadridge Financial SolutionsMorgan Stanley increased its price target for Broadridge Financial Solutions from $176 to $181.
-
Tango Therapeutics and Erasca Announce Phase 1/2 Study Update for PRMT5 InhibitorTango Therapeutics and Erasca have provided an update regarding their ongoing Phase 1/2 clinical study of an oral PRMT5 inhibitor.